Children’s Tumor Foundations World Conference 2024 in Brussels, Belgium from June 21st to 25th, 2024.
With an incidence rate of 1 in 2,500 newborn, people with the genetic deficiency Neurofibromatosis Type 1 (NF1) present a significant patient group worldwide. Almost all struggle with debilitating cutaneous neurofibromas appearing in their skin, sometimes counted in several hundreds located over the entire body. It is therefore a group in urgent need of better therapeutic options than the current surgical and laser-based procedures, which often lead to pain, scarring, and dyspigmentation.
At the CTF conference, TOOsonix will exhibit the world’s first medical device specifically approved for non-invasive treatment of cutaneous neurofibromas in patients with NF1. A recently completed study in Denmark and Sweden demonstrated the safety and efficacy of the TOOsonix focused ultrasound treatment (Link). While it did not remove all tumors in one single session, it demonstrated significant removal or deduction in the majority of them with minimal side effects only.
We are committed to advancing the understanding and treatment of these debilitating tumors and are working hard to improve future therapies.
Visit us at the conference exhibition to learn more: Link
Childrens Tumor Foundation internet site here.
